High Tech Pharm Co. Ltd Cash Flow Conversion Efficiency
High Tech Pharm Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, High Tech Pharm Co. Ltd (106190) has a cash flow conversion efficiency ratio of 0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩6.60 Billion ≈ $4.47 Million USD) by net assets (₩126.99 Billion ≈ $86.06 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of High Tech Pharm Co. Ltd (2014–2024)
Cash flow conversion efficiency of High Tech Pharm Co. Ltd from 2014 to 2024. This chart illustrates how High Tech Pharm Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View High Tech Pharm Co. Ltd (106190) share price today for real-time trading data and today's change.
High Tech Pharm Co. Ltd Cash Flow Conversion Ratio Explained
High Tech Pharm Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
High Tech Pharm Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of High Tech Pharm Co. Ltd ranked by their cash flow conversion efficiency. Also see High Tech Pharm Co. Ltd market cap and net worth for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Avrot Industries Ltd
TA:AVRT
|
0.029x |
|
Tsann Kuen Enterprise Co Ltd
TW:2430
|
0.135x |
|
Duran-Dogan Basim ve Ambalaj Sanayi AS
IS:DURDO
|
0.120x |
|
Clime Capital Ltd
AU:CAM
|
-0.045x |
|
Midsummer AB (publ)
ST:MIDS
|
-0.108x |
|
Heidmar Maritime Holdings Corp. Common Stock
NYSE:HMR
|
-0.322x |
|
Daelim Paper Co.Ltd
KQ:017650
|
0.018x |
|
EKOS
IS:EKOS
|
0.009x |
Annual Cash Flow Conversion Efficiency for High Tech Pharm Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of High Tech Pharm Co. Ltd from 2014 to 2024. Review High Tech Pharm Co. Ltd (106190) FCF generation index to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩119.74 Billion ≈ $81.14 Million |
₩14.69 Billion ≈ $9.96 Million |
0.123x | +351.33% |
| 2023-12-31 | ₩106.99 Billion ≈ $72.51 Million |
₩2.91 Billion ≈ $1.97 Million |
0.027x | +173.37% |
| 2022-12-31 | ₩99.94 Billion ≈ $67.73 Million |
₩-3.70 Billion ≈ $-2.51 Million |
-0.037x | -150.21% |
| 2021-12-31 | ₩93.88 Billion ≈ $63.62 Million |
₩6.93 Billion ≈ $4.69 Million |
0.074x | +191.29% |
| 2020-12-31 | ₩95.14 Billion ≈ $64.48 Million |
₩-7.69 Billion ≈ $-5.21 Million |
-0.081x | -420.83% |
| 2019-12-31 | ₩98.58 Billion ≈ $66.81 Million |
₩2.48 Billion ≈ $1.68 Million |
0.025x | -51.59% |
| 2018-12-31 | ₩103.35 Billion ≈ $70.04 Million |
₩5.38 Billion ≈ $3.65 Million |
0.052x | -2.44% |
| 2017-12-31 | ₩102.19 Billion ≈ $69.26 Million |
₩5.45 Billion ≈ $3.69 Million |
0.053x | +272.82% |
| 2016-12-31 | ₩101.18 Billion ≈ $68.57 Million |
₩1.45 Billion ≈ $981.14K |
0.014x | -89.06% |
| 2015-12-31 | ₩97.20 Billion ≈ $65.87 Million |
₩12.71 Billion ≈ $8.61 Million |
0.131x | +18.32% |
| 2014-12-31 | ₩92.06 Billion ≈ $62.39 Million |
₩10.17 Billion ≈ $6.89 Million |
0.110x | -- |
About High Tech Pharm Co. Ltd
High Tech Pharm Co., Ltd. researches and develops, manufactures, and sells injectable carbapenem-based antibiotics worldwide. The company was incorporated in 1998 and is based in Chungju-si, South Korea.